[go: up one dir, main page]

WO2003066120A1 - Traitement d'une maladie degenerative du disque par transplantation d'un disque allogreffe - Google Patents

Traitement d'une maladie degenerative du disque par transplantation d'un disque allogreffe Download PDF

Info

Publication number
WO2003066120A1
WO2003066120A1 PCT/US2002/003123 US0203123W WO03066120A1 WO 2003066120 A1 WO2003066120 A1 WO 2003066120A1 US 0203123 W US0203123 W US 0203123W WO 03066120 A1 WO03066120 A1 WO 03066120A1
Authority
WO
WIPO (PCT)
Prior art keywords
disc
cells
donor
disc unit
nucleus pulposus
Prior art date
Application number
PCT/US2002/003123
Other languages
English (en)
Inventor
Bret A. Ferree
Original Assignee
Ferree Bret A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferree Bret A filed Critical Ferree Bret A
Priority to AU2002235518A priority Critical patent/AU2002235518A1/en
Priority to PCT/US2002/003123 priority patent/WO2003066120A1/fr
Publication of WO2003066120A1 publication Critical patent/WO2003066120A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3633—Extracellular matrix [ECM]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
    • A61L27/3645—Connective tissue
    • A61L27/3654—Cartilage, e.g. meniscus
    • A61L27/3658—Intervertebral discs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843—Connective tissue
    • A61L27/3852—Cartilage, e.g. meniscus
    • A61L27/3856—Intervertebral discs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/44—Joints for the spine, e.g. vertebrae, spinal discs
    • A61F2/442—Intervertebral or spinal discs, e.g. resilient
    • A61F2002/4445—Means for culturing intervertebral disc tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/44—Joints for the spine, e.g. vertebrae, spinal discs
    • A61F2/442—Intervertebral or spinal discs, e.g. resilient
    • A61F2002/445—Intervertebral disc tissue harvest sites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/38—Materials or treatment for tissue regeneration for reconstruction of the spine, vertebrae or intervertebral discs

Definitions

  • This invention relates generally to the treatment of diseased or traumatized intervertebral discs, and more particularly, to the use of engineered disc tissues and endplate materials in conjunction with such treatment.
  • Intervertebral discs provide mobility and a cushion between the vertebrae.
  • the nucleus pulposus which, in the adult human, is composed of cells and an insoluble extracellular matrix which is produced by the nucleus itself.
  • the extracellular matrix is composed of collagen, proteoglycans, water, and noncollagenous proteins.
  • the cells of the nucleus pulposus have chondrocyte-like features. Blood vessels do not course into the nucleus pulposus. Rather, the cells of the nucleus pulposus of the adult human obtain nutrients and eliminate waste by diffusion through blood vessels in the endplates of the vertebrae adjacent to the disc.
  • the nucleus pulposus is surrounded by the annulus fibrosis, which is composed of cells (fibrocyte-like and chondrocyte-like), collagen fibers, and non-fibrillar extracellular matrix.
  • the components of the annulus are arranged in 15-25 lamellae around the nucleus pulposus.
  • Prosthetic disc devices replace nucleus pulposus and/or annulus fibrosis function.
  • nucleus replacing devices rely on the patient's annulus fibrosis to retain the device and perform annulus functions. Unfortunately, injuries to the annulus often accompany nucleus degeneration or trauma. In addition, the degenerated annulus fibrosis may produce pain in patients with nucleus replacement.
  • Total disc replacements rely on attachment of the prosthetic disc to the vertebral endplates. Various methods of attachment have been described including the use of screws, spikes, and porous ingrowth material. The total disc/vertebral interface can loosen. The problems with prosthesis loosening and the revision surgery of the same are well known in prosthetic knee and hip surgery.
  • This invention resides in a method of treating a diseased or traumatized intervertebral disc located between adjacent vertebrae.
  • a disc unit is harvested from a recently deceased human or animal donor.
  • this donor disc unit preferably includes not only an intervertebral disc having an extracellular matrix, but also a portion of the vertebrae on either side of the disc, including the endplates.
  • An affected disc is surgically removing from a patient, including the vertebral endplates and a portion of the vertebra on either side of the disc, thereby creating a void to be filled, and the donor disc unit is positioned within the surgically created void.
  • the spine may be temporarily locally immobilized following placement of the donor disc unit into the surgically created void.
  • the donor disc unit is processed to kills living cells therewithin, while preserve the extracellular matrix.
  • Nucleus pulposus and/or annulus fibrosis cells are harvested from a healthy intervertebral disc, cultured and transplanted into the donor disc unit. Precursors, or cells which differentiate into cells which provide nucleus pulposus and/or annulus fibrosis cell function may alternatively be used. The harvested cells are preferably kept viable until placed into the disc unit.
  • the method of the invention may further include the step of adding one or more therapeutic substances to the donor disc unit, the transplanted cells, or both prior to transplantation. Such therapeutic substances could include culture media, growth factors, differentiation factors, hydrogels, polymers, antibiotics, anti-inflammatory medications, immunosuppressive medications, or any useful combination thereof.
  • a donor disc unit comprising an intervertebral disc and a portion of adjacent vertebrae, is obtained from a recently deceased human or animal donor, and used to restore disc function and eliminate pain in patients with degenerative disc disease.
  • Autograft nucleus pulposus cells and annulus fibrosis cells are harvested from one or more healthy discs of a patient, preferably the same patient suffering from the disc disease, though any appropriate alternative source may be used, including fetal tissue or human sources, preferably having a familial relationship to minimize or avoid the need for immunosuppressive substances.
  • the harvested cells are cultured then added to nucleus pulposus and annulus fibrosis extracellular matrix, preferably obtained from recently deceased humans or animals, and added to the donor disc unit.
  • the donor disc unit preferably includes a portion of vertebra on either side of the disc.
  • Guidelines for tissue procurement including surgical technique of removal, number of hours between death of the donor and tissue procurement, and testing of the donor for infectious disease, are well described in open literature.
  • tissue is processed to kill the living cells, though care is taken to preserve the extracellular matrix.
  • Guidelines for processing the harvested disc as described are also well known to those skilled in the art. For example, such tissue may be frozen and thawed.
  • the disc being replaced including the vertebral endplates and a portion of the vertebra on either side of the disc are removed from the affected patient. Surgical techniques to remove the disc and a portion of the vertebrae are well known to spine surgeons.
  • the donor disc unit is then placed into the surgically created defect.
  • the replacement disc could be held in position with screws, plates, and/or rods attached between the donor bone and the host vertebrae.
  • the plates or other rigid method of fixation may temporarily extend across the disc, such devices must ultimately removed, or not used at all, or else disc function would not be preserved.
  • synthetic or natural fibers are employed to extend across the disc space and attach to the host vertebrae. Appropriate fibers allow vertebral motion while helping to hold the grafted disc replacement in position.
  • pedicle screws and rods or plates may be used.
  • the screws may be placed percutanously to allow easy removal after the vertebrae have healed.
  • bio-resorbable screws may be used. Growth of the host vertebrae to the donor vertebrae may also be encouraged using growth factors such as bone morphogenetic proteins.
  • Cultured disc cells are added to the donor disc unit a few weeks or months following its transplantation.
  • living disc cells are harvested from a normal disc of the patient with the degenerative disc disease.
  • the living disc cells from the nucleus pulposus and annulus fibrosis are added to the donor nucleus and annulus respectively.
  • the delayed insertion of the cells would allow vascularization of the donor vertebrae prior to cell insertion. Vertebrae vascularization is important for diffusion to and from the transplanted disc cells.
  • the cultured disc cells could be added to the donor disc before transplantation or at the time of transplantation. Culture media could be added to the disc with the transplanted cells.
  • Autologous nucleus pulposus chondrocyte- like cells may be obtained by aspiration or biopsy of healthy discs of the patient.
  • the harvested nucleus pulposus cells are isolated and cultured using standard techniques.
  • the harvested sterile nucleus pulposus is morselized and washed with phosphate buffered saline.
  • the cells are released from the extracellular matrix with 0.2% clostridial collagenase (Worthington CLS II, 140u/mg) and agitated. See
  • the filtered solution is then centrifuged at 1800 rpm to remove the cells.
  • the supernatant above the cells is removed with a micropipette until the cell concentration reaches 5.times.l0.sup.7 cells/cc.
  • the harvested cells are grown in Hamm's F-12 culture media, 10% fetal calf serum, L-glutamine (292.mu.g/cc), penicillin (lOOu/cc), streptomycin
  • Precursor cells of nucleus pulposus cells or annulus fibrosis cells, chondrocytes, or other living cells that could function like nucleus pulposus cells or annulus fibrosis cells or that could differentiate into cells to build a functional nucleus pulposus or annulus fibrosis could also be used.
  • the cultured cells are added to the donor disc through multiple small holes drilled through the annulus fibrosis into the nucleus pulposus.
  • resorbable culture medium tissue growth or differentiation factors (recombinant generated morphogenetic proteins, PDGF, TGF- ⁇ , EGF/TGF- ⁇ , IGF-I, ⁇ FGF), hydrogels, resorbable or nonresorbable synthetic or natural polymers (collagen, fibrin, polyglycolic acid, polylactic acid, polytetrafluoroethylene, etc.), antibiotics, anti-inflammatory medication, immunosuppressive medications, etc. may be beneficial.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

On utilise le disque intervertébral et une partie de vertèbre contiguë obtenue d'un donneur humain récemment décédé ou d'un donneur animal pour restaurer la fonction du disque et éliminer les douleurs ressenties par des patients atteints d'une maladie du disque. Des cellules recueillies et cultivées du noyau gélatineux et/ou de l'anneau fibreux d'un disque normal sont ajoutées au disque du donneur. On peut aussi ajouter au disque transplanté des substances thérapeutiques additionnelles comme un milieu de culture, des facteurs de croissance, des facteurs de différentiation, des polymères hydrogels, des antibiotiques, des médications anti-inflammatoires des médications immunodépressives.
PCT/US2002/003123 2002-02-04 2002-02-04 Traitement d'une maladie degenerative du disque par transplantation d'un disque allogreffe WO2003066120A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002235518A AU2002235518A1 (en) 2002-02-04 2002-02-04 Treating degenerative disc disease through transplantation of allograft disc
PCT/US2002/003123 WO2003066120A1 (fr) 2002-02-04 2002-02-04 Traitement d'une maladie degenerative du disque par transplantation d'un disque allogreffe

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/003123 WO2003066120A1 (fr) 2002-02-04 2002-02-04 Traitement d'une maladie degenerative du disque par transplantation d'un disque allogreffe

Publications (1)

Publication Number Publication Date
WO2003066120A1 true WO2003066120A1 (fr) 2003-08-14

Family

ID=27732068

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/003123 WO2003066120A1 (fr) 2002-02-04 2002-02-04 Traitement d'une maladie degenerative du disque par transplantation d'un disque allogreffe

Country Status (2)

Country Link
AU (1) AU2002235518A1 (fr)
WO (1) WO2003066120A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023156A1 (fr) * 2003-08-21 2005-03-17 Sdgi Holdings, Inc. Implants allogeniques/xenogeniques et methodes permettant d'augmenter ou de reparer des disques intervertebraux
US7556649B2 (en) 2000-04-07 2009-07-07 Zimmer Orthobiologics, Inc. Methods and compositions for treating intervertebral disc degeneration
US7713303B2 (en) 2002-09-18 2010-05-11 Warsaw Orthopedic, Inc. Collagen-based materials and methods for augmenting intervertebral discs
US7731981B2 (en) 2002-11-15 2010-06-08 Warsaw Orthopedic, Inc. Collagen-based materials and methods for treating synovial joints
US7744651B2 (en) 2002-09-18 2010-06-29 Warsaw Orthopedic, Inc Compositions and methods for treating intervertebral discs with collagen-based materials
US7887593B2 (en) 2002-09-18 2011-02-15 Warsaw Orthopedic, Inc. Method of implanting natural tissue within the vertebral disc nucleus space using a drawstring
US7947649B2 (en) 2008-04-14 2011-05-24 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered GDF-5 formulations
US7956028B2 (en) 2006-12-14 2011-06-07 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US7964561B2 (en) 2007-06-29 2011-06-21 Advanced Technologies And Regenerative Medicine, Llc Protein formulations for use at elevated temperatures
US8058237B2 (en) 2007-08-07 2011-11-15 Advanced Technologies & Regenerative Medicine, LLC Stable composition of GDF-5 and method of storage
US8118779B2 (en) 2006-06-30 2012-02-21 Warsaw Orthopedic, Inc. Collagen delivery device
US8399619B2 (en) 2006-06-30 2013-03-19 Warsaw Orthopedic, Inc. Injectable collagen material
US8419739B2 (en) 2009-08-24 2013-04-16 Amir A. Jamali Method and apparatus for allograft disc transplantation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060053A (en) 1993-04-30 2000-05-09 Children's Medical Center Corp. Injectable chondrocyte-carrier suspension for treatment of vesicoureteral reflux and incontinence
US6080579A (en) * 1997-11-26 2000-06-27 Charlotte-Mecklenburg Hospital Authority Method for producing human intervertebral disc cells
WO2001076654A1 (fr) * 2000-04-07 2001-10-18 Sulzer Biologics Inc. Techniques et compositions permettant de traiter la degenerescence des disques intervertebraux
WO2002000142A2 (fr) * 2000-06-29 2002-01-03 Mount Sinai Hospital Disque intervertebral
US6340369B1 (en) * 1999-08-13 2002-01-22 Bret A. Ferree Treating degenerative disc disease with harvested disc cells and analogues of the extracellular matrix

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060053A (en) 1993-04-30 2000-05-09 Children's Medical Center Corp. Injectable chondrocyte-carrier suspension for treatment of vesicoureteral reflux and incontinence
US6080579A (en) * 1997-11-26 2000-06-27 Charlotte-Mecklenburg Hospital Authority Method for producing human intervertebral disc cells
US6340369B1 (en) * 1999-08-13 2002-01-22 Bret A. Ferree Treating degenerative disc disease with harvested disc cells and analogues of the extracellular matrix
WO2001076654A1 (fr) * 2000-04-07 2001-10-18 Sulzer Biologics Inc. Techniques et compositions permettant de traiter la degenerescence des disques intervertebraux
WO2002000142A2 (fr) * 2000-06-29 2002-01-03 Mount Sinai Hospital Disque intervertebral

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; FRICK, STEVEN L. (1) ET AL: "Lumbar intervertebral disc transfer: A canine study.", XP002215569, retrieved from STN Database accession no. 1994:445252 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; KATSUURA, AKITOMO (1) ET AL: "Experimental study of intervertebral disc allografting in the dog.", XP002215570, retrieved from STN Database accession no. 1995:16727 *
MIZUNO H ET AL: "Tissue engineering of a composite intervertebral disc", TISSUE ENGINEERING, LARCHMONT, NY, US, vol. 6, no. 6, December 2000 (2000-12-01), pages 666, XP002195743, ISSN: 1076-3279 *
OKUMA M ET AL: "REINSERTION OF STIMULATED NUCLEUS PULPOSUS CELLS RETARDS INTERVERTEBRAL DISC DEGENERATION: AN IN VITRO AND IN VIVO EXPERIMENTAL STUDY", JOURNAL OF ORTHOPAEDIC RESEARCH, THE JOURNAL OF BONE AND JOINT SURGERY, INC.,, US, vol. 18, no. 18, 2000, pages 988 - 997, XP001064826, ISSN: 0736-0266 *
SPINE, (1994) VOL. 19, NO. 16, PP. 1826-1835. *
SPINE, (1994) VOL. 19, NO. 21, PP. 2426-2432. *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7556649B2 (en) 2000-04-07 2009-07-07 Zimmer Orthobiologics, Inc. Methods and compositions for treating intervertebral disc degeneration
US7713303B2 (en) 2002-09-18 2010-05-11 Warsaw Orthopedic, Inc. Collagen-based materials and methods for augmenting intervertebral discs
US7744651B2 (en) 2002-09-18 2010-06-29 Warsaw Orthopedic, Inc Compositions and methods for treating intervertebral discs with collagen-based materials
US7887593B2 (en) 2002-09-18 2011-02-15 Warsaw Orthopedic, Inc. Method of implanting natural tissue within the vertebral disc nucleus space using a drawstring
US7731981B2 (en) 2002-11-15 2010-06-08 Warsaw Orthopedic, Inc. Collagen-based materials and methods for treating synovial joints
KR101090631B1 (ko) 2003-08-21 2011-12-08 워쏘우 오르쏘페딕 인코포레이티드 추간판 확장 또는 복원을 위한 동종/이종 임플란트
JP2007502653A (ja) * 2003-08-21 2007-02-15 ウォーソー・オーソペディック・インコーポレーテッド 椎間円板移植片
US7309359B2 (en) 2003-08-21 2007-12-18 Warsaw Orthopedic, Inc. Allogenic/xenogenic implants and methods for augmenting or repairing intervertebral discs
CN1859883B (zh) * 2003-08-21 2010-07-14 华沙整形外科股份有限公司 用于增强或修复椎间盘的同种异体/异种植入物及方法
US9011543B2 (en) 2003-08-21 2015-04-21 Warsaw Orthopedic, Inc. Methods for augmenting or repairing intervertebral discs with allogenic/xenogenic implants
WO2005023156A1 (fr) * 2003-08-21 2005-03-17 Sdgi Holdings, Inc. Implants allogeniques/xenogeniques et methodes permettant d'augmenter ou de reparer des disques intervertebraux
US8399619B2 (en) 2006-06-30 2013-03-19 Warsaw Orthopedic, Inc. Injectable collagen material
US8118779B2 (en) 2006-06-30 2012-02-21 Warsaw Orthopedic, Inc. Collagen delivery device
US7956028B2 (en) 2006-12-14 2011-06-07 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US8435943B2 (en) 2006-12-14 2013-05-07 Advanced Technogies And Regenerative Medicine, Llc Protein stabilization formulations
US8895506B2 (en) 2006-12-14 2014-11-25 DePuy Synthes Products, LLC Protein stabilization formulations
US7964561B2 (en) 2007-06-29 2011-06-21 Advanced Technologies And Regenerative Medicine, Llc Protein formulations for use at elevated temperatures
US8058237B2 (en) 2007-08-07 2011-11-15 Advanced Technologies & Regenerative Medicine, LLC Stable composition of GDF-5 and method of storage
US7947649B2 (en) 2008-04-14 2011-05-24 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered GDF-5 formulations
US8419739B2 (en) 2009-08-24 2013-04-16 Amir A. Jamali Method and apparatus for allograft disc transplantation

Also Published As

Publication number Publication date
AU2002235518A1 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
US6344058B1 (en) Treating degenerative disc disease through transplantation of allograft disc and vertebral endplates
US6352557B1 (en) Treating degenerative disc disease through transplantion of extracellular nucleus pulposus matrix and autograft nucleus pulposus cells
US6648919B2 (en) Transplantation of engineered meniscus tissue to the intervertebral disc
US6454804B1 (en) Engineered tissue annulus fibrosis augmentation methods and apparatus
US6340369B1 (en) Treating degenerative disc disease with harvested disc cells and analogues of the extracellular matrix
US6419702B1 (en) Treating degenerative disc disease through transplantation of the nucleus pulposis
US6685695B2 (en) Method and apparatus for providing nutrition to intervertebral disc tissue
US6793677B2 (en) Method of providing cells and other biologic materials for transplantation
US6648918B2 (en) Treating degenerative disc disease through the transplantation of dehydrated tissue
US6645247B2 (en) Supplementing engineered annulus tissues with autograft of allograft tendons
US6648920B2 (en) Natural and synthetic supplements to engineered annulus and disc tissues
US11357889B2 (en) Native soft tissue matrix for therapeutic applications
US6755863B2 (en) Rotator cuff repair using engineered tissues
US20030026788A1 (en) Use of extracellular matrix tissue to preserve cultured cell phenotype
US20170304058A1 (en) Implant for Repairing a Cartilage Defect
US9981063B2 (en) Biosynthetic composite for osteochondral defect repair
US20070156238A1 (en) Multi-layered matrix, method of tissue repair using the same, and multi-layered implant prepared thereof
CN101495067B (zh) 椎间盘移植物和移植方法
WO2003066120A1 (fr) Traitement d'une maladie degenerative du disque par transplantation d'un disque allogreffe
US20090054983A1 (en) Bioresorbable bone implant
US20220168356A1 (en) Allografts containing viable cells and methods therof
EP3644908B1 (fr) Implant bioabsorbable combiné avec un disque intervertébral composite obtenu à partir d'un tissu
US8697139B2 (en) Method of intervertebral disc treatment using articular chondrocyte cells
KR102766983B1 (ko) 생체 활성 및 생분해성 물질을 이용한 정형외과적 질환 치료 장치 및 방법
RU2269961C2 (ru) Способ аутотрансплантации иммобилизованных стромальных стволовых клеток костного мозга

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP